Tech Company Financing Transactions

Incyclix Bio Funding Round

Boxer Capital, Eshelman Ventures and private investors participated in a $30 million Series B funding round for Incyclix Bio. The financing was announced on 3/31/2022.

Transaction Overview

Company Name
Announced On
3/31/2022
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors

Boxer Capital (Lead Investor)

Eshelman Ventures

Private Investors (Sid Subramony)

RA Capital

Proceeds Purpose
Proceeds from the financing will be used to support the clinical development of Incyclix Bio's lead compound, INX-315, a novel, potent and selective CDK2 inhibitor with compelling preclinical efficacy and safety data. Incyclix Bio expects to initiate a proof-of-concept Phase 1/2 study of INX-315 in CDK4/6-resistant and Cyclin E-overexpressed cancers, including breast and ovarian cancer.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 Park Offices Drive Suite 355 Research
Triangle Park, NC 27709
USA
Email Address
Overview
Developer of small molecule inhibitors of cyclin-dependent kinases (CDKs) intended to provide treatment for patients with advanced and resistant cancers. The company's inhibitors help to achieve the potent and selective inhibition of elusive CDK targets, enabling pharmaceutical companies and medical practitioners with novel drugs to help and improve the treatment of cancer patients.
Profile
Incyclix Bio LinkedIn Company Profile
Social Media
Incyclix Bio Company Twitter Account
Company News
Incyclix Bio News
Facebook
Incyclix Bio on Facebook
YouTube
Incyclix Bio on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Patrick Roberts
  Patrick Roberts LinkedIn Profile  Patrick Roberts Twitter Account  Patrick Roberts News  Patrick Roberts on Facebook
Co-Founder
Jay Strum
  Jay Strum LinkedIn Profile  Jay Strum Twitter Account  Jay Strum News  Jay Strum on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/31/2022: Reema Health venture capital transaction
Next: 3/31/2022: Pacto venture capital transaction

 

Share this article

 


About Our VC Transactions Data

We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary